Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
Want to see SCNI full AI Analyst Report?
SCNI Stock Chart & Stats
$0.78
-$0.11(-3.01%)
At close: 4:00 PM EST
$0.78
-$0.11(-3.01%)
Day’s Range― - ―
52-Week Range$0.41 - $6.18
Previous CloseN/A
Volume8.73K
Average Volume (3M)101.31K
Market Cap
$1.56M
Enterprise Value$1.20M
Total Cash (Recent Filing)$989.00K
Total Debt (Recent Filing)$2.36M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Jul 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding3,535,489
10 Day Avg. Volume127,573
30 Day Avg. Volume101,310
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)1.27
P/FCF Ratio-0.27
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue1.04
Enterprise Value/Gross Profit-0.71
Enterprise Value/Ebitda0.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet / Lower LeverageSharp debt reduction and positive equity materially lower financial leverage, improving solvency and reducing default risk. This strengthens capacity to fund R&D and strategic moves with less interest strain, enhancing durable access to capital over the next several quarters.
Strategic CDMO AcquisitionAcquiring Recipharm Israel to create a CDMO subsidiary diversifies Scinai beyond pure R&D into fee-for-service manufacturing. A growing CDMO can provide recurring revenue, improve cash generation and customer relationships, supporting pipeline funding and business resilience.
Top-line Growth TrendRevenue growth, though from a small base, shows early commercial or service traction and validates go-to-market capability. Sustained top-line expansion can reduce reliance on financing, help absorb fixed R&D costs, and improve prospects for margin recovery over several quarters.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow (~-$6M annually) indicates the business consumes capital faster than it generates it. This creates ongoing dependency on external financing, elevates dilution and refinancing risk, and limits runway for clinical programs absent material revenue gains.
Negative Gross Profit And Large LossesNegative gross margins and substantial operating losses show unit economics are not yet established. Without clear margin improvement or significant scale, profitability appears distant, pressuring equity and constraining options to self-fund development over the medium term.
Nasdaq Listing Compliance RiskA Nasdaq minimum-bid deficiency creates a regulatory timeline with real delisting risk. Loss of U.S. listing would reduce liquidity and institutional access, likely forcing dilutive measures or structural fixes and complicating capital raises and partnerships over coming months.
Scinai Immunotherapeutics News
SCNI FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was $0.41 and its highest was $6.18 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is $1.56M.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is Jul 07, 2026 which is in 37 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on Apr 01, 2026. The company reported -$0.604 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.604.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 3,535,489 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of -$0.604 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.105%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in SCNI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Technical Analysis
Ownership Overview
―
Insiders
0.42% Other Institutional Investors
99.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---